Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis
用户1vmuUF1gAVhM
12天前
35
10
已完结
1. 系统已在2026-01-04 10:00:42对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1097/hep.0000000000001084
文献链接: https://journals.lww.com/10.1097/HEP.0000000000001084
其他信息:
出版社: Ovid Technologies (Wolters Kluwer Health)
作者: Zobair M. Younossi; Maria Stepanova; Andrei Racila; Linda Henry; Dominic Labriola; Rebecca Taub; Fatema Nader
